The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Respiratory syncytial virus and influenza activity are on the rise in parts of the country, particularly among young children, according to the CDC's latest respiratory virus updates. Overall, the ...

Big Data, Real World, Multi-State Study Finds RSV Vaccine Highly Effective in Protecting Older Adults Against Severe Disease, Hospitalization and Death Oct. 17, 2024 — This multi-state study is ...

WAUSAU, Wis. (WSAW) --- Doctors recommend that people learn about the RSV vaccine as cold and flu season approaches Wisconsin. RSV, or Respiratory Syncytial Virus, is a common contagious virus that ...

Pima County Health Dept alerts about RSV season, urging high-risk groups to get vaccinated and describing symptoms and ...

Almost all children will get RSV during their first two years, but each year up to 80,000 children are hospitalized due to it. Now, a new FDA approved vaccine can protect your baby—even before the ...

For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associated ...

The RSV vaccine is recommended from September through January and provides protection for around six months after birth. Both immunization options are effective in reducing the risk of a baby being ...

This year, there are more options for those most susceptible to RSV, including a new vaccine and updated RSV vaccine guidance ...

Canada's vaccine advisers recommend RSV shots for infants "The news Ontario has access to new RSV-prevention products is very, very exciting and should be top of mind for any family with a young ...

This license enables Vaxxas to prepare for a clinical trial of the first Respiratory Syncytial Virus (RSV) vaccine delivered to the skin using Vaxxas’ novel high-density microarray patch (HD-MAP).

Vaxxas’ worldwide license from the NIH enables the company to create the first needle-free, room-temperature stable RSV vaccine to enter clinical studies. The next-generation DS2 RSV vaccine ...